| “Donald Tashkin’s is a tale cannabis pushers like to repeat. The physician and professor at UCLA’s David Geffen School of Medicine set out to prove — via a study funded by the National Institutes on Drug Abuse — that marijuana is bad for you. Instead, a long-term study found no solid link between marijuana use and lung cancer, in sharp contrast to tobacco terrible effects on health.”
|
| “Similar findings were repeated all over the world. In a collection and review of studies on marijuana’s effect on the lungs, published in the June issue of the Annals of the American Thoracic Society, Tashkin concludes that compared to tobacco smoking, heavy marijuana use has “relatively small and far lower” risks.
This despite an average joint marijuana having four times the tar of a typical American Spirit. How can this be? It’s worth remembering that this is not a new development — Tashkin’s long-term study was published in 2006. And well before that — as in the 19th Century, when cannabis tinctures and other marijuana medicines were sold in pharmacies — doctors were prescribing marijuana as a treatment for asthma patients.” |
Breathe Easy: A Marijuana Study Finds No Lung Cancer Links
“Donald Tashkin‘s is a tale cannabis pushers like to repeat. The physician and professor at UCLA‘s David Geffen School of Medicine set out to prove — via a study funded by the National Institutes on Drug Abuse — that marijuana is bad for you. Instead, a long-term study found no solid link between marijuana use and lung cancer.
Similar findings were repeated all over the world. In a review of studies on marijuana’s effect on the lungs, published in the June issue of the Annals of the American Thoracic Society, Tashkin concludes that compared to tobacco smoking, heavy marijuana use has “relatively small and far lower” risks.”
More: http://www.sfweekly.com/2013-06-19/news/ucla-medical-marijuana-cancer/full/
Cannabis Cures Cancer Without Poison
“Isn’t it strange that doctors can legally administer poison in the form of chemotherapy and radiation as well as numerous toxic pharmaceuticals and yet one of nature’s medicines- found to greatly assist cancer patients- which can be prepared by any common person without harmful side effects, is illegal and can send a person to prison for its possession?
There are numerous studies, now spanning the globe, revealing the miraculous healing properties of cannabis oil and its ability to cure cancers and other ailments without poisoning the body.
Cannabis oil, or Hemp oil contains many healing benefits including a high amount of protein as well as essential fatty acids, including the harder to come by GLA’s – known to reduce inflammation and slow the growth of cancer cells. As far as essential fatty acids go, we need a particular ratio of Omega 3, Omega 6 and GLA’s in our body for good health. Omega 3 comes largely from fish, Omega 6 can be found in many of our cooking oils such as olive and sunflower, but GLA is only found in a few sources such as borage oil, spirulina and hemp. Hemp oil happens to contain the perfect 2:5:1 ratio of omega 3, 6 and GLA’s. Interesting.
As far as cancer goes, the research proof has been out there for a while…
Cannabis oil has been shown to shrink and even cure cancers in all the studies conducted without poisoning the body. Isn’t it time to give the people a safe, legal alternative to such an ailment? Let us put aside our fears and greed and support nature in being our medicine, so she can further support us in healing.”
More: http://guardianlv.com/2013/06/cannabis-cures-cancer-without-poison/
Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy.
“Cannabinoids show promise for the treatment of various medical conditions such as emesis, anorexia, pain, cancer, multiple sclerosis, Parkinson’s disease and glaucoma.
The objective of the present work was to assess the feasibility of developing cannabinoid loaded poly-ε-caprolactone (PCL) microparticles prepared by the oil-in-water emulsion-solvent evaporation technique as a suitable dosage form for their administration.
In vitro cell viability studies demonstrated the antitumoral activity of CBD released from microparticles. After 4 and 7 days of incubation, CBD in microspheres significantly inhibited the growth of MDA-MB-231 cells by 60% as compared to the 50% attained with free drug.
The results suggest that PCL microparticles could be an alternative delivery system for long-term cannabinoid administration, showing potential therapeutic advantages over free drug.”
Preparation and characterization of Δ9-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines.
“Cannabinoids present an interesting therapeutic potential as antiemetics, appetite stimulants in debilitating diseases (cancer, AIDS and multiple sclerosis), analgesics, and in the treatment of multiple sclerosis and cancer, among other conditions.
However, despite their high clinical potential, only few dosage forms are available to date. In this paper, the development of Δ9-tetrahydrocannabinol (THC) biodegradable microspheres as an alternative delivery system for cannabinoid parenteral administration is proposed. Tetrahydrocannabinol was encapsulated into biodegradable microspheres by the oil-in-water (o/w) emulsion solvent evaporation method. Several formulations were prepared using different drug:polymer ratios. The influence of antioxidant (α-tocopherol acetate) concentration on the release of THC from the microparticles was studied. Elevated process yield and entrapment efficiencies were achieved.The in vitro drug release studies showed that the encapsulated drug was released over a two week period.
As THC has shown therapeutic potential as anticancer drug, the efficacy of the microspheres was tested on different cancer cell lines.
Interestingly, the microspheres were able to inhibit cancer cell proliferation during the nine-day study period.
All the above results suggest that the use of biodegradable microspheres would be a suitable alternative delivery system for THC administration.”
Acute Δ9-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice.
“Nonsteroidal anti-inflammatory drugs (NSAIDs), which are among the most widely used analgesics in the world, cause gastrointestinal inflammation that is potentially life-threatening.
Although inhibitors of endocannabinoid catabolic enzymes protect against gastropathy in fasted NSAID-treated mice, the gastroprotective effects of Δ9-tetrahydrocannabinol (THC), the primary psychoactive component of marijuana, have yet to be investigated…
These data indicate that the phytocannabinoid Δ9-THC protects against diclofenac-induced gastric inflammatory tissue damage at doses insufficient to cause common cannabinoid side effects.”
Synthetic Compounds From Marijuana Appear to Fight HIV
“Synthetic anti-inflammatory compounds derived from the active ingredient of marijuana appear to show potential as anti-HIV agents, Wired.co.uk reports. Publishing their findings in the Journal of Leukocyte Biology, researchers from Temple University School of Medicine’s Department of Pathology and Laboratory Medicine and Center for Substance Abuse Research (CSAR) studied synthetic derivations of THC, or tetrahydrocannabinol, a key chemical compound in marijuana, in cultures of HIV-infected cells.
Cannabinoids, which are the primary active compounds in marijuana, bind to proteins called CB2 receptors on the surface of macrophage immune cells. The CB2 site may play a role in reducing inflammation in the central nervous system, which is a major concern for people living with HIV, even those whose virus is fully suppressed thanks to antiretrovirals (ARVs). It is the CB1 receptors, mostly found in neurons in the brain, however, that cause marijuana’s psychoactive effects. So synthetic THC that has been developed to bind only to CB2 receptors should not make people stoned.
It is believed that macrophage cells, which are found throughout the body, are a major component of the HIV reservoir and are probably the first cells infected after sexual transmission of the virus.
Using a non-clinical cell model, the investigators treated HIV-infected macrophages with one of three different synthetic compounds that bind to CB2. By periodically measuring the activity of the enzyme reverse transcriptase, which HIV needs to replicate itself, the investigators concluded after a seven-day period that all three compounds fought HIV replication.
The findings suggest that these “CB2 agonists” could be a potential addition to ARV therapy, and also that the human immune system could be prompted to fight the virus using similar mechanisms.”
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
“Drugs that target one of the two cellular receptors stimulated by the active ingredient in marijuana may prove to be effective at blocking a form of HIV that has been linked to faster disease progression during late stages of the infection.
Though the PLoS One research report highlighting these findings—published March 20 by a team of scientists at Mt. Sinai School of Medicine in New York—stops short of concluding that marijuana is one of nature’s best antiretrovirals, the authors suggest that further study of cannabinoids is needed to ultimately discover drugs with both antiviral and symptom-reducing properties.
Marijuana—purchased legally or illegally and either smoked or ingested—along with its synthetic counterpart Marinol (dronabinol) are used by many people living with HIV to manage various symptoms of illness, including pain, depression and weight loss.
The numerous effects of marijuana are the result of chemical interactions between the drug’s active ingredient, tetrahydrocannabinol (THC), and two receptors on a variety of cells in the body: cannabinoid receptor 1 (CR1) and cannabinoid receptor 2 (CR2)…
Using a cannabinoid receptor agonist—a THC-like compound—her team found that activation of CR2 inhibited CXCR4-tropic HIV infection. It did this, not by altering the number of CXCR4 receptors on CD4 cells—this is a therapeutic approach being explored by others—but rather by blocking the receptor’s “signaling process” and interaction with HIV.
According to the PLoS One report, activation of CR2 blocked the ability of CXCR4-tropic virus to infect other cells by 30 to 60 percent. “This inhibition is pronounced in resting cells,” the researchers explain, “which are a target of CXCR4-tropic HIV.”
“Developing a drug that triggers only [CR2] as an adjunctive treatment to standard antiviral medication may help alleviate the symptoms of late-stage AIDS and prevent the virus from spreading,” said Dr. Costantino in an accompanying news announcement.”
More: http://www.aidsmeds.com/articles/hiv_marijuana_cannabinoids_1667_22119.shtml#.Ub8Pcix9Dhs.twitter
Turned-Off Cannabinoid Receptor Turns on Colorectal Tumor Growth – MDAnderson
“Researchers find CB1 suppresses tumors, a new potential path for treatment, prevention.”
“New preclinical research shows that cannabinoid cell surface receptor CB1 plays a tumor-suppressing role in human colorectal cancer, scientists report in the Aug. 1 edition of the journal Cancer Research.
CB1 is well-established for relieving pain and nausea, elevating mood and stimulating appetite by serving as a docking station for the cannabinoid group of signaling molecules. It now may serve as a new path for cancer prevention or treatment.
“Potential application of cannabinoids as anti-tumor drugs is an exciting prospect, because cannabinoid agonists are being evaluated now to treat the side-effects of chemotherapy and radiation therapy,” DuBois said.
“Turning CB1 back on and then treating with a cannabinoid agonist could provide a new approach to colorectal cancer treatment or prevention.”
Cannabinoids are a group of ligands that serve a variety of cell-signaling roles. Some are produced by the body internally (endocannabinoids). External cannabinoids include manmade versions and those present in plants, most famously the active ingredient in marijuana (THC).”
Turned-off Cannabinoid Receptor Turns On Colorectal Tumor Growth – CB1 Suppresses Tumors, A New Potential Path For Treatment, Prevention
“New preclinical research shows that cannabinoid cell surface receptor CB1 plays a tumor-suppressing role in human colorectal cancer, scientists report in the Aug. 1 edition of the journal Cancer Research.
CB1 is well-established for relieving pain and nausea, elevating mood and stimulating appetite by serving as a docking station for the cannabinoid group of signaling molecules. It now may serve as a new path for cancer prevention or treatment.
“Potential application of cannabinoids as anti-tumor drugs is an exciting prospect, because cannabinoid agonists are being evaluated now to treat the side-effects of chemotherapy and radiation therapy,” DuBois said. “Turning CB1 back on and then treating with a cannabinoid agonist could provide a new approach to colorectal cancer treatment or prevention.”
Cannabinoids are a group of ligands that serve a variety of cell-signaling roles. Some are produced by the body internally (endocannabinoids). External cannabinoids include manmade versions and those present in plants, most famously the active ingredient in marijuana (THC).”